Calliditas Therapeutics AB ADR (CALT): Price and Financial Metrics

Calliditas Therapeutics AB ADR (CALT): $22.53

-0.32 (-1.40%)

POWR Rating

Component Grades














  • Sentiment is the dimension where CALT ranks best; there it ranks ahead of 72.44% of US stocks.
  • CALT's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
  • CALT's current lowest rank is in the Momentum metric (where it is better than 9.48% of US stocks).

CALT Stock Summary

  • The ratio of debt to operating expenses for Calliditas Therapeutics AB is higher than it is for about merely 0.49% of US stocks.
  • With a price/sales ratio of 12,549.94, Calliditas Therapeutics AB has a higher such ratio than 99.72% of stocks in our set.
  • Revenue growth over the past 12 months for Calliditas Therapeutics AB comes in at -99.16%, a number that bests only 0.73% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Calliditas Therapeutics AB are TFFP, MRSN, VNRX, ONTX, and SINT.
  • Visit CALT's SEC page to see the company's official filings. To visit the company's web site, go to

CALT Stock Price Chart Interactive Chart >

Price chart for CALT

CALT Price/Volume Stats

Current price $22.53 52-week high $38.00
Prev. close $22.84 52-week low $20.50
Day low $22.21 Volume 17,965
Day high $22.92 Avg. volume 32,721
50-day MA $27.31 Dividend yield N/A
200-day MA $29.23 Market Cap 589.63M

Calliditas Therapeutics AB ADR (CALT) Company Bio

Calliditas Therapeutics AB provides pharmaceutical products for patients with niche indications. It focuses on development and commercialization of the product candidate Nefecon intended for treatment of patients with the inflammatory renal disease IgA nephropathy. The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.

CALT Latest News Stream

Event/Time News Detail
Loading, please wait...

CALT Latest Social Stream

Loading social stream, please wait...

View Full CALT Social Stream

Latest CALT News From Around the Web

Below are the latest news stories about Calliditas Therapeutics AB that investors may wish to consider to help them evaluate CALT as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning. investor!

William White on InvestorPlace | September 16, 2021

Updated regulatory timeline for review of MAA in Europe

Calliditas Therapeutics AB (publ) ("Calliditas" or the "Company") (Nasdaq Stockholm: CALTX) (Nasdaq: CALT), a biopharma company focused on identifying, developing and commercializing novel treatments in orphan indications, today announced that the European Medicine Agency's (EMA) Committee for Human Medicinal Products (CHMP)) has decided to continue the assessment of the marketing authorization application (MAA) for Nefecon under standard procedure assessment timelines.

Yahoo | September 16, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, investor!

William White on InvestorPlace | September 15, 2021

The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC) aTyr Pharma, Inc. (NASDAQ: LIFE) (reacted to positive analyst action following a positive clinical readout announced Monday) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) BELLUS Health Inc. (NASDAQ: BLU) Itamar Medical Ltd. (NASDAQ: ITMR) IVERIC bio, Inc. (NASDAQ: ISEE) Kezar Life Sciences, Inc. (NASDAQ: KZR) PPD, Inc. (NASDAQ: P

Yahoo | September 15, 2021

Calliditas Therapeutics Stock Falls As FDA Pushes Nefecon PDUFA Goal Date To December

The FDA has extended the PDUFA goal date for Calliditas Therapeutics AB's (NASDAQ: CALT) application seeking accelerated approval for Nefecon. Nefecon is an oral formulation targeting down-regulation of IgA1 to treat primary IgA Nephropathy (IgAN). The new goal date is December 15 compared to the previous September 15. The FDA has requested further analyses of the NeflgArd trial data, which the company has provided to the FDA. The amendment mainly provides additional eGFR and other related analy

Yahoo | September 15, 2021

Read More 'CALT' Stories Here

CALT Price Returns

1-mo 1.05%
3-mo -21.06%
6-mo -23.11%
1-year -3.80%
3-year N/A
5-year N/A
YTD -32.99%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9097 seconds.